Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

iShares Russell 2000 BuyWrite ETF (NY:IWMW)

39.58 -0.02 (-0.05%)
Streaming Delayed Price Updated: 10:00 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 BuyWrite ETF

< Previous 1 2 3 4 Next >
News headline image
Joby Inks $61.5 Million Deal To Acquire Another Ready-To-Use Facility In Ohio As It Eyes Doubling eVTOL Production ↗
The new facility spans more than 700,000 feet and is ready for immediate use, the California-based company said. 
Via Stocktwits
Rumble Rallies After Unveiling Tether-Powered Crypto Wallet – Retail Expects Stock To Surpass The $10 Mark ↗
Via Stocktwits
Zeta Global Shares Rose After It Deepens Collaboration with OpenAI ↗
Via Stocktwits
Rigetti Computing Stock Draws Retail Buzz After Quantum Timeline Slips And Insider Sale Surfaces ↗
Via Stocktwits
News headline image
WULF Stock Rises 3% Pre-Market After Keefe More Than Doubles Price Target ↗
Keefe Bruyette upgraded TeraWulf to an ‘Outperform’ rating from ‘Market Perform’, citing its optimism on the company’s high-performance computing transition. 
Via Stocktwits
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 
Via Stocktwits
Topics Supply Chain
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
Via Stocktwits
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗
Via Stocktwits
American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act ↗
Via Stocktwits
News headline image
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗
The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. 
Via Stocktwits
Topics Death
News headline image
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug ↗
The company also announced the pricing of a $20 million registered direct offering. 
Via Stocktwits
News headline image
Why Is UUUU Stock Rising Today? ↗
The company said that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance. 
Via Stocktwits
Topics Government World Trade
News headline image
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts ↗
The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 
Via Stocktwits
Archer Aviation Stock Jumps On Tech Deal With Karem For Military Aircraft — Retail Seeks Tangible Progress ↗
Via Stocktwits
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review ↗
Via Stocktwits
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
Via Stocktwits
News headline image
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗
The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 
Via Stocktwits
News headline image
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 
Via Stocktwits
News headline image
After A Sharp Rally In 2025, Ramaco Is Doubling Down With $100M Share Buyback ↗
Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder... 
Via Stocktwits
News headline image
EchoStar’s SpaceX Stake Is Driving UBS, Citi Price Target Revisions ↗
UBS lowered EchoStar’s price target to $125 from $128 while Citi raised the firm’s price target to $111 from $87, according to TheFly. 
Via Stocktwits
News headline image
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. 
Via Stocktwits
News headline image
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ ↗
Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 
Via Stocktwits
Rezolve AI Stock Shot Up Over 27% Today — How Did Microsoft, Google Help Double 2025 ARR Expectations? ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Is GLSI Stock Rising Today? ↗
Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 
Via Stocktwits
News headline image
Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential ↗
Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.” 
Via Stocktwits
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
Compass Diversified Stock Plunges On ‘Most Significant Loss’ After Fraud Forces Removal Of Three Years Of Financials ↗
The company has removed financial information for the years 2022 to 2024 from its website, citing non-reliance. 
Via Stocktwits
Topics Fraud
News headline image
Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗
Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks. 
Via Stocktwits
News headline image
Kohl’s Traders Just Got The CEO They Wanted — And the Stock’s Weekly Breakout Says It All ↗
Last week, KSS stock soared nearly 60%, marking its best weekly performance this year, after Michael Bender was confirmed as full-time CEO. 
Via Stocktwits
News headline image
Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum ↗
Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. 
Via Stocktwits
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.